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Abstract
Depression is one of the most common and important neuropsychiatric symptoms in Parkin-
son’s disease and often becomes worse as Parkinson’s disease progresses. However, the
underlying mechanisms of depression in Parkinson’s disease are not clear. The aim of our
study was to find genetic features related to depression in Parkinson’s disease using an
imaging genetics approach and to construct an analytical model for predicting the degree of
depression in Parkinson’s disease. The neuroimaging and genotyping data were obtained
from an openly accessible database. We computed imaging features through connectivity
analysis derived from tractography of diffusion tensor imaging. The imaging features were
used as intermediate phenotypes to identify genetic variants according to the imaging
genetics approach. We then constructed a linear regression model using the genetic fea-
tures from imaging genetics approach to describe clinical scores indicating the degree of
depression. As a comparison, we constructed other models using imaging features and
genetic features based on references to demonstrate the effectiveness of our imaging
genetics model. The models were trained and tested in a five-fold cross-validation. The
imaging genetics approach identified several brain regions and genes known to be involved
in depression, with the potential to be used as meaningful biomarkers. Our proposed model
using imaging genetic features predicted and explained the degree of depression in Parkin-
son’s disease appropriately (adjusted R2 larger than 0.6 over five training folds) and with a
lower error and higher correlation than with other models over five test folds.
Introduction
Parkinson’s disease (PD) is the second most common neurodegenerative disorder [1]. PD is
characterized primarily as a movement disorder, but recent research indicates that a variety of
non-motor symptoms including constipation, sleep disturbances, diabetes, cognitive decline,
and depression may play a role in PD development [2]. Among these symptoms, depression is
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the most common non-motor symptom of PD, occurring in around 40–50% of all patients
diagnosed with PD [3,4]. Depression can predate symptoms of PD for several years before the
worsening of motor symptoms and belongs to the group of non-motor features that might pre-
dict the development of PD [5,6]. Depression in PD (DPD) can aggravate all other symptoms,
including the worsening of motor symptoms, rapid disease progression, and reduced cognitive
function [7]. DPD is one of the major causes of poor quality of life and disability in PD patients
[8]. However, DPD has not yet been fully explored [9,10].
The criteria involved in general depression and DPD are subject to bias as they are either
psychiatric scales or clinical interviews. Thus, neuroimaging techniques have been used to
reduce subjective bias and better understand DPD or general depression. Many studies that
have used single photon emission tomography (SPECT) and positron emission tomography
(PET) were mainly focused on the dopaminergic and serotonergic systems [11,12]. Magnetic
resonance imaging (MRI) techniques have been invaluable for neuroscientists, providing
insight into the structure, biochemistry, and function of the living human brain. Diffusion ten-
sor imaging (DTI), a variant of MRI, can quantify the integrity of white matter fiber tracts non-
invasively. Recent work using DTI has shown that altered structural white matter connectivity
in the fronto-limbic systems distinguishes major depressive disorder (MDD) from healthy
controls [13,14]. In this study, we used probabilistic tractography to characterize the regions of
interest (ROIs) that affect depression. The fiber information from DTI might be helpful in dis-
tinguishing the degree of depression.
However, several factors impede our ability to diagnose a person with a psychiatric condi-
tion including depression based on neuroimaging: 1) there is considerable variation in brain
imaging among people with the same diagnosis, 2) psychiatric conditions can present quite
differently in different individuals, 3) different psychiatric conditions often share similar
symptoms, and, finally, 4) similar groups of brain areas are involved in diverse psychiatric con-
ditions. Psychiatric disorders such as depression are difficult to characterize using neuroimag-
ing alone. We tried to overcome this limitation by adopting an imaging genetics approach that
uses both neuroimaging and gene data.
Both genetic and environmental factors contribute to individual differences in brain func-
tion and behavior [15]. Although it remains unclear to what degree each of these factors con-
tributes to variation in brain function, it is likely that genetics contribute to a significant
portion of the variance. Genes that are weakly related to psychiatric disorders such as depres-
sion are relatively strongly related to the function of neural systems involved in processing cog-
nitive and emotional information in the brain. There are probably no individual genes for
psychiatric disorders, but rather genetic variations that impact the relevant information pro-
cessing in the brain [16]. The imaging genetics approach is more sensitive than the conven-
tional genome-wide association approach (GWAS) as it integrates imaging information as an
intermediate phenotype [16,17]. Ideally, the relationship between the regional pattern of neu-
roimaging and genetic variants could explain the underlying biological mechanisms of depres-
sion or DPD and provide an intuitive concept of DPD mediated by brain systems affected by
genetic variants [15].
The aim of this study was to identify genetic features affecting DPD using the imaging
genetics approach and to construct an analytical model for predicting the degree of depression
in PD. We hypothesized that a neuroimaging genetics approach would be sensitive enough to
identify genetic features as biomarkers that could explain the degree of DPD. Furthermore, we
constructed other models using imaging features only and genetic features based on references
and compared them against our image genetics model.
Imaging genetics for depression in Parkinson’s disease
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Methods
Subjects and imaging data
This study was a retrospective analysis of anonymized data and institutional review board (IRB)
approval was obtained at Sungkyunwkan University. All data were obtained with informed
written consent in accordance with established human subject research procedures expressed in
the Declaration of Helsinki. Our study was performed in full accordance with the local IRB
guidelines. We used diffusion MRI, T1-weighted MRI and DNA genotyping data of 81 patients
with PD obtained from the Parkinson’s Progression Markers Initiative (PPMI) database [17].
Patient information, including age, sex, and clinical assessment (e.g. the geriatric depression
scale [GDS], Movement Disorder Society sponsored unified Parkinson’s disease rating scale
[MDS-UPDRS][18]), were collected for each subject at a baseline visit, as shown in Table 1.
Additional clinical scores of State Trait Anxiety Inventory (STAI), Montreal Cognitive Assess-
ment (MoCA), and Questionnaire for Impulsive-Compulsive Disorder (QUIP) were collected
[19–21]. PD was diagnosed using the criteria established by the PPMI consortium [17]. GDS is
a clinical score indicating the degree of depression. Subjects who have a GDS of 6 or more were
considered to be depressed patients [22]. We randomly sub-sampled the data so that sex ratio
(female to male) was two, which is the sex ratio in PD [23]. Table 1 shows the clinical informa-
tion of the DPD and non-depressed patients with PD (nDPD) patients in this study.
Diffusion MRI and T1-weighted MRI data were obtained from the PPMI database [17].
T1-weighted MRI were obtained using the following parameters on a 3T scanner (repetition
time [TR] = 2,300 ms, echo time [TE] = 2.98 ms, image matrix = 240 × 256 × 176, and voxel
resolution = 1 × 1 × 1 mm3). Diffusion MRI were obtained using the following parameters on
a 3T scanner (b = 1,000 s/mm2, 64 diffusion gradient directions with one b0 image, image
matrix = 116 × 116 × 72, and voxel resolution = 1.98 × 1.98 × 2 mm3). Our study considered
two types of information (i.e., neuroimaging and genetic information) and many procedures
are necessary to process them. The schematic of the overall processing steps is given in Fig 1
[24]. Details regarding the procedures are provided later in this study.
Genetic data and quality control
We obtained DNA samples genotyped by NeuroX genotyping arrays from the PPMI. The fol-
lowing procedure pertains to the genetic data of the PPMI. All available DNA samples were
Table 1. Patient information.
DPD nDPD p-value
Number of subjects 36 45 -
Age 61.63±10.60 63.08±9.83 0.52
Sex (M:F) 24:12 30:15 -
MDS-UPDRSa 34.72±16.33 33.82± 14.04 0.79
STAIb 67.34±18.17 62.96±16.87 0.27
MoCAc 27.06±1.80 27.16±2.54 0.84
QUIPd 0.31±0.58 0.18±0.53 0.28
GDSe 6.86±1.12 4.58±0.75 <10−16
aMDS-UPDRS: Movement Disorder Society-sponsored unified Parkinson’s disease rating scale.
bSTAI: State Trait Anxiety Inventory [19].
cMoCA: Montreal Cognitive Assessment.
dQUIP: Questionnaire for Impulsive-Compulsive Disorder [21].
eGDS: geriatric depression scale.
https://doi.org/10.1371/journal.pone.0211699.t001
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genotyped by using NeuroX as genotyping arrays. Briefly, NeuroX was proposed to cover
more than 240,000 exonic variants so that neurodegenerative disease could be studied effec-
tively [25,26]. These neurodegenerative variants influencing specific diseases contain loci. Loci
were derived from the maximum completed meta-analyses of PD patients and normal controls
(NC), which identified known PD mutations and unusual or high-risk variants [26]. Genotyp-
ing was performed according to the Illumina protocol using an Immunochip array [25,26].
Fig 1. Overview of neuroimaging, reference-based genetics, and imaging genetics processing steps.
https://doi.org/10.1371/journal.pone.0211699.g001
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The Immunochip is an Illumina Infinium iSelect HD Custom Genotyping array including
195,806 single nucleotide polymorphisms (SNPs) in 196,524 polymorphisms [25–27].
We performed quality control of the genetic data by applying the Enhancing Neuro Imag-
ing Genetics through Meta-Analysis (ENIGMA) protocol [28] using Plink v1.09 software [29].
The ENIGMA protocol included the following processes: 1) call rate check per subject, 2) sex
check, 3) sibling pair identification and 4) population stratification using multi-dimensional
scaling. In addition, the SNPs that did not meet the quality control criteria (minor allele
frequency< 0.01; genotype call rate< 95%; Hardy-Weinberg equilibrium < 10−6) were fil-
tered out of the dataset [24,28,29]. SNPs were only kept if they did not belong to the Caucasian
population according to the HapMap3 reference population. The age, sex ratio, and
MDS-UPDRS of the DPD and nDPD groups were matched (Table 1). The above section is
described as the “SNP genotyping data” section of PPMI subject in Fig 1.
Neuroimaging processing and selection of imaging features
All imaging data were pre-processed using the Functional Magnetic Resonance Imaging of the
Brain (FMRIB) Analysis Group Software Library (FSL) [30]. Structural T1 images were skull-
stripped and nonlinearly registered onto the common Montreal Neurological Institute (MNI)
space. DTI data were corrected for distortion and movement artifacts and subsequently used
to perform probabilistic tractography. Head motion and image distortions induced by eddy
currents were corrected by applying a 3D full-affine alignment of each image to the mean no-
diffusion-weighting (b0) image. DTI data were averaged and concatenated after the correction
of distortion. DTI images were co-registered onto the common MNI space as with T1 images,
then we adopted the automated anatomical labeling (AAL) atlas defined on the MNI space to
specify the ROIs.
Probabilistic tractography algorithm implemented in FSL software was applied to extract
the fiber connection in all ROIs [31]. We performed Bayesian Estimation of Diffusion Parame-
ters Obtained using Sampling Techniques (bedpost tool in FSL) [32] on diffusion data, which
allows the modeling of crossing fibers within each voxel. Next, we used the probtrackX tool to
generate a connectivity distribution between each ROI that guides multiple fiber samples start-
ing from a seed voxel to a specified target region. The algorithm propagated a line from the
center of the seed voxel to the direction of not only the dominant ROI but also that of non-
dominant ones until the line strayed out. Fiber tracking ended when fiber direction changed
rapidly and probabilistic tractography was performed in the native space for each participant.
Here, all 90 ROIs were used as seeds. Each brain region was selected as the seed region, and its
connectivity probabilities to each of the other 89 regions were calculated. The computed fiber
streamlines remained within the masked regions. One thousand fiber streamlines were gener-
ated from each voxel within the seed region, and only those that reached the target region were
retained as the final white matter connection. The streamlines were terminated once they
reached a target region.
Connectivity analysis is a representative method of analyzing complex systems such as the
brain, and it uses nodes and edges to analyze a given system. Connectivity analysis requires
nodes to be specified so that correlations among nodes can be computed. We considered 90
ROIs specified by the atlas via image co-registration as nodes in a graph [33,34]. Each edge was
defined as fiber probability connecting a pair of regions. We applied a weighted and undi-
rected network model to perform connectivity analysis. The constructed graph is commonly
referred to as the structural connectivity matrix as it reflects structural connectivity via white
matter fiber tracts. We computed the degree centrality (DC), the number of direct connections
to all other nodes with respect to a given node, among several network parameters to quantify
Imaging genetics for depression in Parkinson’s disease
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the structural connectivity [34]. The data used were collected from the 12 centers. We adopted
a dummy coding regression model to remove multi-site effects for the DC value [35].
There were many (i.e., 90) DC values computed from the ROIs and thus we adopted the
least absolute shrinkage and selection operator (LASSO) algorithm to select regional imaging
features that could characterize DPD. The LASSO is a penalized regression model that selects a
sparse set of features that can explain a dependent variable. We sought to find imaging features
that were related to DPD; thus, the dependent variable was the GDS score. The LASSO
requires a smoothness term (λ), which was set by minimizing the mean squared residual in a
10-fold cross-validation. Finally, k non-zero beta values were selected as significant imaging
features to appropriately explain the GDS. The above section is described as the “Imaging
data” section of PPMI subject in Fig 1.
SNP selection from imaging genetics
We chose the imaging features selected by LASSO variable selection as intermediate pheno-
types and performed imaging genetics analysis to detect genetic variants associated with the
intermediate phenotype. Plink software was employed for imaging genetics analysis [29]. Lin-
ear regression by conventional genetics analysis was used to evaluate the association of allele
genotypes with the intermediate phenotypes with covariates included for age and sex. SNPs
were identified above a threshold of corrected empirical-p < 0.01 with Bonferroni correction.
To provide a sufficient condition for evaluating the association, we considered genetic variants
as significant SNPs only if they were identified more than once in different intermediate phe-
notypes (i.e., more than one ROI from the previous section). This was to improve the consis-
tency of the association between the significant SNPs and the identified imaging features. It is
likely that the number of selected SNPs is still excessive (possibly in the hundreds) as with
many genetic association studies [36]. We adopted another layer of SNP selection to reduce
the number of selected SNPs. Similar to selecting imaging features, we applied the LASSO
framework using GDS scores as the dependent variable to select SNPs. The smoothness term
(λ) of LASSO was set using the approach described before. The above section is described as
the “Imaging genetics” and “SNP genotyping data” sections of PPMI subject in Fig 1.
Construction of imaging genetics based linear regression model
A five-fold cross-validation was adopted separating the training and the test data. The data
were divided into five folds. Four folds were used to train and construct the models and the
remaining fold was used to test the constructed models. For each training fold, we constructed
a linear model using multiple linear regression based on the features selected from the previous
steps to explain the GDS score. Our proposed model was constructed using genetic features
from imaging genetics approach that used both the imaging and genetic features. Our regres-
sion model used age, sex, and MDS-UPDRS as covariate variables:
Y ¼ a� SNPþ b� COVþ ε
, where Y was the GDS, SNP were imaging genetics features, COV were co-variants, α and β
were estimated coefficient, and ε was the error. The quality of multiple linear regression was
assessed with adjusted R2 values. We applied our trained model to the left out test fold five
times each time using a different test fold. This resulted in five sets of performance metrics of
the models, which were averaged to yield a single scalar value. We assessed the performance of
the prediction using Pearson’s correlation between actual and predicted GDS. Root mean
squared (RMS) error was also used to quantify how well the prediction of the actual GDS
worked.
Imaging genetics for depression in Parkinson’s disease
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Construction of other multiple regression models for comparison
We constructed two other linear models to compare with our imaging genetic based model.
This process also performed in a five-fold cross-validation fashion as described above.
A) Multiple regression model with only neuroimaging features. We constructed a lin-
ear model with only neuroimaging features. The imaging features were obtained using the pro-
cedure described in “Neuroimaging processing and selection of imaging features” section to
compute intermediate phenotypes. These imaging features not new ones for this model but
intermediate phenotypes used as part of the imaging genetic analysis.
B) Multiple regression model with conventional genetic features. We constructed a lin-
ear model with SNPs related to DPD based on references. This approach did not consider
imaging genetics approach. Among gene-specific research related to DPD, there were no refer-
ences. Thus, we investigated genes related to depression. There are 5,992 human genes for
depression ranked by a relevance score according to the GeneCards database [37,38]. We
chose the top 50 genes from the gene list associated with depression and identified SNPs that
were also found in the PPMI data. Similar to the imaging genetic approach, we selected a few
SNPs using the LASSO framework. We composed the model in the same way as before using
several genetic features resulting from LASSO.
These two other models were compared to our model to show that the features obtained by
imaging genetics could better than those obtained with conventional neuroimaging and genet-
ics analysis procedures.
Results
Selected imaging features from structural connectivity
We used diffusion MRI, T1-weighted MRI and DNA genotyping data of 81 patients with PD
obtained from the PPMI database [17]. Structural connectivity analysis based on probabilistic
tractography was performed and we identified imaging features that were significantly related
to the degree of depression using the LASSO [39,40]. The selected imaging features were
strongly correlated with the GDS score and this does not mean that imaging features between
DPD and nDPD would be significantly different. We have reported the DC values of the iden-
tified imaging features obtained from the LASSO selection procedure for patients with DPD
and nDPD to further demonstrate the potential effectiveness of the selected imaging features
(Table 2). The DC values of these eight regions were used as intermediate phenotypes in imag-
ing genetics analysis and were also used to construct the neuroimaging only model.
Table 2. The selected imaging features from structural connectivity.
Regions from atlas Degree centrality p-value
# Name DPD nDPD
31 Anterior cingulate and paracingulate gyri (Left) 8.31±8.85 2.43±2.00 0.277
38 Hippocampus (Right) 8.04±9.52 2.78±3.29 0.035
41 Amygdala (Left) 1.66±2.50 0.77±0.90 <10−4
42 Amygdala (Right) 2.08±2.32 1.07±1.12 0.343
57 Postcentral gyrus (Left) 6.51±7.22 1.06±1.68 0.022
67 Precuneus (Left) 7.76±8.44 2.07±1.50 0.104
83 Temporal pole: superior temporal gyrus (Left) 2.69±3.49 1.14±0.95 0.001
87 Temporal pole: middle temporal gyrus (Left) 0.86±1.22 0.53±0.55 0.003
DC values are reported as the mean ± standard deviation (SD) format. The values were reported for two groups
(DPD and nDPD) to show how the imaging features affect depression in PD.
https://doi.org/10.1371/journal.pone.0211699.t002
Imaging genetics for depression in Parkinson’s disease
PLOS ONE | https://doi.org/10.1371/journal.pone.0211699 February 11, 2019 7 / 18
Genotype data
We obtained DNA samples genotyped by NeuroX genotyping arrays from the PPMI that were
processed using the PPMI protocol. Quality control was performed on the genetic data by
applying the ENIGMA protocol [28]. At first, the genotype data contained 267,607 SNPs of
619 people (409 males and 210 females). To reduce the population stratification effect, we used
418 Caucasians from 619 subjects with complete imaging measurements at baseline. We
excluded SNPs if they met the criteria: 218,004 SNPs had a minor allele frequency< 0.01,
12,718 SNPs had a genotype call rate< 95%, and 220 SNPs had a Hardy-Weinberg
equilibrium < 10−6. After frequency and genotype pruning, 48,769 SNPs remained. We then
proceeded with imaging genetics approach using only these quality-controlled SNPs.
Selected SNPs from imaging genetics
We applied the imaging genetics approach using the identified imaging features (Table 2) as
intermediate phenotypes to find SNPs. After a Bonferroni-corrected significant threshold of
empirical-p < 0.01, more than 500 SNPs per ROI remained. Only 503 SNPs were retained
after the SNP filtering which considered SNPs associated with at least two imaging features.
After using LASSO selection, we were left with 18 SNPs that described the GDS appropriately
(Table 3).
Selected SNPs based on references for comparison
We searched for SNPs related to DPD not using the imaging information but using references
for comparison. We searched for genes related to depression because there were no references
among gene-specific research related to DPD. We found 5,992 genes associated with depres-
sion from the GeneCards database, which integrates information about genes, proteins, and
disease [37,38]. We chose the top 50 genes sorted by relevance score for depression and 954
SNPs were identified that were also in the PPMI database. We selected three SNPs associated
with GDS using the LASSO framework (Table 4). The three SNPs associated with DPD were
exm2267347, exm1187499, and exm-rs9303521.
Validation and prediction of linear models
The three linear regression models were constructed using features from imaging genetics,
structural connectivity, and conventional references to predict GDS in a five-fold cross-valida-
tion. The first model of imaging genetics was our proposed model and it jointly considered
imaging and genetic features. Our proposed model using imaging genetics features showed
meaningful correlation (r = 0.749, p = 0.001; averaged) between the predicted and real GDS
over five left out test folds. The mean RMS error between the predicted and actual GDS was
0.991 (standard deviation [SD] 0.242). The second model used only imaging features and
showed a moderate correlation and RMS error (r = 0.371, p = 0.175, RMS error = 1.370 [SD
0.329]; averaged) between the predicted and real GDS. The model using only the reference-
based genetic features achieved the correlation RMS error that were similar to the model with
only neuroimaging features (r = 0.278, p = 0.157, RMS error = 1.452 [SD 0.296]; averaged).
The prediction plots of the three models are given in Fig 2. We found that the adjusted R2 val-
ues for models using only imaging features and the reference-based genetic features were less
than 0.3, while the adjusted R2 for our proposed model was larger than 0.6 over five training
folds. We confirmed that genetic features derived from the intermediate phenotype of imaging
features could provide complementary information to explain the degree of depression (deter-
mined by GDS), whereas imaging features and genetic features used alone contributed less.
Imaging genetics for depression in Parkinson’s disease
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The features adopted in these three models came from different sources of information. Com-
bining the models could provide complementary information, which may lead to an improved
explanation of GDS. There are three sets of features and there could be many distinct
Table 3. Selected SNPs from imaging genetics.
SNP Gene CHRa Base-pair location Minor allele Intermediate phenotype (#)b Asymptotic p-value
exm-rs11265263 - - - A 41 0.0005
42 0.0077
87 0.0033
exm2261278 NRXN1 2 50565462 C 41 0.0004
42 0.0078
87 0.0033
exm-rs2629046 - - - C 41 0.0017
83 0.0055
exm2265730 ARHGAP24 4 86808963 G 38 0.0011
42 0.0067
83 0.0087
exm2266008 - - - G 38 0.0027
42 0.0020
exm-rs6556756 LOC101927835 5 163889280 G 57 0.0062
67 0.0063
NeuroX-rs56107012 - - - G 38 0.0043
42 0.0036
exm847519 LOXL4 10 100017453 G 41 0.0002
87 0.0033
exm883966 OR52N2 11 5842310 T 31 0.0003
87 0.0031
exm952147 PDGFD 11 103818395 C 31 0.0074
83 0.0065
exm1092110 PCK2 14 24572932 A 41 0.0046
83 0.0023
87 0.0096
exm2272098 RAB15 14 65428165 C 57 0.0041
67 0.0061
exm1179562 PEAK1 15 77471361 A 31 0.0212
38 0.0020
42 0.0057
exm1185136 SLC28A1 15 85478729 A 41 0.0079
42 0.0007
exm-rs4517902 LOC284395 19 29851078 C 42 0.0053
83 0.0009
87 0.0029
exm1513594 ZNF772 19 57985460 T 38 0.0006
42 0.0043
SNPs without matching gene-related information, such as chromosome (CHR) and base-pair location, have blank entries. We described only intermediate phenotypes
with asymptotic p-values less than 0.01.
a CHR: chromosome.
b Intermediate phenotype (#) refers to the numerical labels of the ROI names in “Regions from atlas” of Table 2. This was done to improve readability of the table.
https://doi.org/10.1371/journal.pone.0211699.t003
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combinations of the feature sets. Detailed results from the all possible combined models are
shown in Figures A and B in S1 File.
We identified SNPs that could explain GDS well using the imaging genetics approach lim-
ited to PD patients. It is still possible that the identified SNPs could also be present in NC par-
ticipants using the same approach. We applied the same imaging genetics approach to NC
participants (n = 69) from the PPMI database. Unfortunately, no imaging features that
explained GDS well were computed from the NC group. This led to applying the imaging
genetics approach infeasible as there were no intermediate phenotypes available. If the SNPs
identified in the PD group were indeed present in the NC group, the SNPs should be able to
explain GDS well in the NC group as well. We applied the linear model of the identified SNPs
learned from PD to the NC group. The results showed that the identified SNPs were not effec-
tive at explaining the degree of depression in the NC group with a very low adjusted R2 value
(i.e., < 0.01, closet to zero). Taken together, we believe the identified SNP were only effective
at explain GDS within PD group and thus the features could be specific to DPD.
Discussion
Psychological phenomena are difficult to characterize using neuroimaging or genetic analysis
alone as the given diagnosis spans a wide spectrum of symptoms. Some argue that diagnosis is
becoming less relevant due to this problem [41,42]. The DPD diagnostic criteria used in this
study were also affected by this problem. Depression occurs in approximately 40% of PD
patients and DPD and nDPD patients share many symptoms such as cognitive decline, motor
impairment, and helplessness, which makes separating DPD from nDPD difficult [6,7,43].
Depression is multifactorial and its manifestation varies significantly when it accompanies
neurodegenerative diseases [5–8,44]. Therefore, in this study, we constructed models to pre-
dict the degree of depression in PD patients rather than the diagnosis of depression. We identi-
fied several features that indicate the degree of depression in PD using the imaging genetics
approach. The features were used to predict the degree of depression and the performance was
enhanced when features derived from imaging genetics were used. If each of the resulting
SNPs from imaging genetics is studied in more detail, these SNPs could be used as biomarkers
related to DPD in the future.
Imaging genetics analysis is better than conventional analysis because imaging observations
are used as intermediate phenotypes [16]. Others have adopted psychiatric or behavior inter-
mediate phenotypes and have reported improved biological characterization and validation of
genetic effects [45]. Imaging genetics can describe a neural system that is affected by genetic
variation and identify polymorphisms beyond a simple statistical association. Imaging genetics
is a powerful bottom-up approach to elucidate biologically valid knowledge of previously
unknown mechanisms such as the detailed mechanism of psychiatry. Therefore, imaging
Table 4. Selected SNPs from references.
SNP Gene CHR a Base-pair location Minor allele GIFtSb Relevance score
exm2267347 COL2A1 12 48375568 G 54 18.34
exm1187499 POLG 15 89859994 A 52 20.75
exm-rs9303521 CRHR1 17 43805194 T 53 17.84
The GeneCards Inferred Functional Score (GIFtS) uses the Genecards annotations to produce scores aimed at predicting the degree of a gene’s functionality. The
relevance score is the Novoseek score of the relevance of the disease to the gene based on literature text-mining algorithms.
a CHR: chromosome.
b GIFtS: GeneCards Inferred Functional Score
https://doi.org/10.1371/journal.pone.0211699.t004
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genetics could be used for the discovery of neural circuits that convert genetic influences into
behavior. These imaging genetics approaches might enable us to further understand the neuro-
biology of DPD.
We identified 18 SNPs related to eight regional structural connectivity measures that con-
tributed to predicting the depression-related score (i.e., GDS) in PD patients. The SNPs were
matched with genes. Among the identified genes, several genes were overexpressed in the
identified ROIs as intermediate phenotypes. NRXN1 and LOC284395 are known to be related
to the anterior cingulate cortex [37]. LOC284395 is also related to amygdala [37]. The
Fig 2. The prediction plots of the three models. (a), (b), and (c) show the actual and predicted GDS from Models using neuroimaging features, conventional genetic
features, and imaging genetics features, respectively. The dashed line indicates the identity line. (d) shows the actual GDS and predicted GDS for each subject using our
proposed model using imaging genetics features (N = 81).
https://doi.org/10.1371/journal.pone.0211699.g002
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ARHGAP24 and RAB15 are known to affect hippocampus [46,47]. The structural connectivity
in the anterior cingulate cortex, hippocampus, and amygdala showed significant contributions
to predicting the GDS score. The identified regions are involved in the corticolimbic system
[48,49], and previous studies revealed limbic structures were related with DPD [50,51]. The
corticolimbic system is known as an important pathway associated with the dopamine secre-
tion [48,52,53]. Similar to our results, previous studies already revealed limbic structures are
closely related with DPD patients, regardless of neurotransmitter. Even though the exact
mechanism of DPD patients was fully understood, dopaminergic medications improve DPD
patients and dopaminergic involvements could be considered based on our results [54]. In
addition to the dopaminergic neurotransmission system, the neurodegenerative processes in
PD patients involve the serotonergic or cholinergic system [53], and the limbic structures
including hippocampus and amygdala were associated with serotonin and acetylcholine
[15,55,56] that affects dopamine deficit and increases the risk of depression [57]. Taken
together, the identified genes might affect the structural connectivity of various structures such
as anterior cingulate cortex, amygdala, and hippocampus, which might alter the degree of
depression in PD via many neurotransmitter systems. The possible downstream pathway from
involved SNP/gene is left for future work as there is a very limited literature associating SNP/
gene with depression related pathways. Interestingly, our imaging genetics model identified 18
SNPs and they did not overlap with the three SNPs identified in the reference-based model.
We were able to identify the three SNPs if we relaxed the first selection procedure with an
empirical p-value threshold of 0.05 and the constraint of association with two or more imaging
features.
In addition to the regions in the corticolimbic system, we identified postcentral gyrus, pre-
cuneus, and temporal pole. These regions were also reported to be related to DPD patients
[7,12,58]. The alteration in postcentral gyrus was associated with the cortical-basal ganglia cir-
cuit that is known as an important system that controls motor symptoms in PD patients [59].
The precuneus is generally known as the region highly connected with the posteromedial cor-
tex [33]. It is known to be involved in motivation, planning, and social behavior and part of
the default mode network which can be altered in depressive patients [60]. Krug et al. found
that the left precuneus was more activated in healthy subjects carrying a specific gene found to
be overrepresented in patients suffering from bipolar disorder, depression, or schizophrenia
[60,61]. The temporal pole is heavily involved in facial emotion processing [62] that is known
to be strongly linked with depression [63]. Based on our results, the SNP/Gene in our study
may be associated with various neuronal circuits with many neurotransmitter systems. There-
fore, with disease progression, PD patients may present with diverse motor and non-motor
symptoms, including depression, from involvements of aforementioned systems.
We used DC of structural connectivity because psychiatric disorders such as depression
were thought to be related to the complex interactions of the brain regions, and thus we con-
sidered a more network-oriented complex measure such as DC as the intermediate phenotype
compared to simple measures such as fractional anisotropy (FA) and mean diffusivity (MD).
In the current study, we found larger DC values in DPD patients compared to the nDPD
patients (Table 2). Among the identified regions, hippocampus, amygdala, postcentral gyrus,
and temporal pole showed significant between-group differences in DC values between DPD
and nDPD groups. The hippocampus and amygdala are involved in the limbic system that reg-
ulates emotion and memory; thus, abnormalities in these regions appear to contribute to the
pathophysiology of mood disorders [64]. A previous study observed that the depressed patients
showed microstructural alteration in the hippocampus in terms of FA and MD [65] indicating
the structural connectivity of hippocampus could be altered in depressed patients. One study
explored the structural connectivity in the PD patients with sleeping behavior disorder that is
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highly correlated with depression [66,67]. They reported increased centrality in the patients of
sleeping behavior disorder in PD in the amygdala and hippocampus compared to the patients
without sleeping behavior disorder in PD [66]. Those studies were collectively consistent with
our results in that the regions in the limbic system are related to depression. We could not find
prior studies related to postcentral gyrus and temporal pole. Further studies are needed in
these regions to properly study the DPD.
We conducted additional experiments to see if the imaging features were related to clinical
scores provided by the PPMI database. If the imaging features were affected by other psychiat-
ric disorders, they could be used to the predict clinical score related to the psychiatric disorder.
We predicted STAI, MoCA and QUIP scores using the same imaging features in a regression
framework. The models that predicted MoCA and QUIP scores showed very low correlations
(r = -0.040, p = 0.221; r = 0.074, p = 0.164; averaged; QUIP and MoCA, respectively) between
the predicted and actual scores. When STAI was predicted with the same imaging features, we
observed a slightly lower correlation (r = 0.225, p = 0.188; averaged) than the existing correla-
tion with GDS (r = 0.371, p = 0.175; averaged). This is consistent with literature that depres-
sion and anxiety are linked strongly, and they co-occur frequently [68]. This confounding
issue needs to be validated with future studies with carefully curated data.
Imaging genetics is a sensitive analysis for identifying additional genetic information that
impacts brain function [16]. Still, the SNPs we identified in this study need further validation
using independent large-scale cohorts because most genes expressed in the brain are likely to
have variable effects and the link between the identified SNPs and depression could be weak.
The results of our study need to be interpreted in the context of its limitations. Our study is
also limited by the small number of samples. This is mainly because we used data from a
research database. This issue was partly mitigated by two-tiered selection approaches, where
only a small number of SNPs were selected for the models. Our findings need to be validated
on a larger cohort in the future. The imaging data in our study were obtained from nine differ-
ent sites, but all nine sites adopted the same image acquisition protocol using the same MRI
scanner model (Siemens 3T scanner) to reduce confounding effects. In addition, we added
multi-center information as a nuisance covariate to account for possible confounding effects
in the computation of DC derived from structural connectivity analysis. Despite many previ-
ous studies, various neurotransmitters were reported to be involved in PD patients and the
mechanism of depression in PD patients has not been fully understood yet. Depression in PD
and non-PD patients could be clinically different. Depression is a very heterogeneous disorder
and also common in non-PD patients. Depression is already known as a pre-motor symptom
for PD [69] and related with prognosis in PD patients [70]. Furthermore, unlike the depression
in non-PD subjects, the dopaminergic system is regarded to be involved and dopaminergic
medication could be helpful for the DPD patient [54].
We combined two types of distinct information to predict the degree of depression. The
genetic information is rather fixed, but imaging could be performed depending on the patient’s
condition. Our model combining imaging and genetics information could be applied whenever
a patient undergoes new imaging and thus could be used for the early prediction of depression.
If detected, patients could be directed to many non-drug therapy options that are only available
in the early stages of depression. Our study is also the first to propose a model that can explain
the degree of depression (determined by GDS) in PD using diffusion MRI and SNP data.
Supporting information
S1 File. The validation and prediction results of combining the three models in main text.
This S1 File included the validation and prediction results of constructed additional models by
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integrating different combinations of our proposed model using imaging genetic features, the
model using only neuroimaging features, and the model using only conventional genetic fea-
tures.
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